Fingolimod
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Fingolimod and local guidelines before prescribing.
Mechanism
Sphingosine-1-phosphate receptor modulator trapping lymphocytes in nodes.
Uses
Relapsing multiple sclerosis.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
First-dose bradycardia, macular oedema, infections, raised LFT, skin cancers.
Interactions
Beta-blockers, QT-prolonging drugs; live vaccines.
Contraindications and cautions
Heart block, recent MI, active infection
Monitoring
ECG, LFT, eye check, FBC
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Caution in severe hepatic impairment
Overdose and reversal
Supportive
Special advice
Observe at first dose with ECG and BP for 6 hours; check varicella immunity.
More from the textbook: uses, cautions and other points
- Fingolimod , siponimod, ozanimod, ponesimod | Oral S1P modulators | Bradycardia with the first dose (monitoring), macular oedema , shingles (check varicella immunity), skin cancer, rebound on stopping; teratogenic
Neurology: Anatomy, Physiology and Pharmacology - Avoid teriflunomide (washout needed), fingolimod and other S1P modulators (stop 2 months before, with rebound risk), cladribine, alemtuzumab (wait 4 months) and mitoxantrone.
Neurology: Multiple Sclerosis and inflammatory disease - Avoid MS drugs - interferon beta, natalizumab and fingolimod can make NMOSD worse .
Neurology: Multiple Sclerosis and inflammatory disease - Avoid MS DMTs (interferon, natalizumab, fingolimod).
Neurology: Multiple Sclerosis and inflammatory disease - S1P receptor modulators (tablets) - fingolimod , ozanimod, ponesimod, and siponimod (active secondary progressive MS).
Neurology: Multiple Sclerosis and inflammatory disease - Fingolimod / siponimod | S1P modulators; first-dose bradycardia, macular oedema, rebound on stopping; worsen NMOSD (fingolimod); siponimod for active SPMS.
Neurology: Multiple Sclerosis and inflammatory disease - Natalizumab: PML risk - JCV antibody index. Fingolimod: bradycardia, macular oedema, rebound. Alemtuzumab: thyroid disease and ITP.
Neurology: Multiple Sclerosis and inflammatory disease - Lymphopenia and immunosuppression | Steroids, fludarabine, alemtuzumab, cladribine, rituximab (B cells), fingolimod, chemotherapy
Haematology: Anatomy Physiology and Pharmacology